Pharma Focus Europe

Tetra Pharm Technologies Introduces Innovative Pain Relief Drug in the United Kingdom

Wednesday, March 20, 2024

Following its successful launch in Germany last year, the cannabinoid-based product XATEPA® is set to be introduced to patients in the United Kingdom during the second quarter of 2024.

XATEPA® is a meticulously developed medication aimed at providing effective relief from chronic pain, as well as alleviating discomfort associated with MS spasms and nausea. The innovative sublingual spray is engineered as a facilitative technology to optimize cannabinoid absorption and effectiveness.

"We are excited to bring XATEPA® to the United Kingdom market. We firmly believe that this product holds the potential to significantly improve the lives of many patients. Our focus remains on continually investing in expanding our pipeline of new drug candidates targeting the endocannabinoid system and associated medical conditions. By launching XATEPA® across various markets, we aim to bolster our long-term research and development endeavors, which remain our utmost priority," stated Martin Rose, Chief Executive Officer of Tetra Pharm Technologies.

For the distribution of XATEPA® in the United Kingdom, Tetra Pharm Technologies has forged a strategic partnership with 4C LABS Ltd., a company collaborating with an extensive network of clinics, physicians, and patient organizations. This agreement ensures that patients across the United Kingdom and Channel Islands can access XATEPA®, as it will be available for prescription by all doctors, physicians, and clinics.

"4C LABS is thrilled to be the exclusive distributor of Tetra Pharm Technologies' suite of cannabinoid-based prescription drugs in the United Kingdom. There has been a significant demand from doctors and patients alike for medications that offer a convenient and consistent delivery method, and XATEPA® fulfills this need with its innovative formulation and precise dosage per spray," commented James Smith, Chief Revenue Officer of 4C LABS Ltd.

Tetra Pharm Technologies plans to introduce XATEPA® to several additional European and overseas markets throughout 2024.

 

Source: prnewswire.com

magazine-slider-img
Thermo Fisher Scientific - mRNA ServicesWorld Orphan Drug Congress 2024World Vaccine Congress Europe 2024Advanced Therapies USA 2024
cytiva